METHOD OF TREATING RECURRENT HIGH-GRADE CEREBRAL GLIOMAS Russian patent published in 2025 - IPC A61N5/10 A61B6/03 C07K16/46 A61B6/50 A61B5/55 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and radiation therapy, and can be used in complex treatment of recurrent high-grade gliomas (rHGG) in adults. At the contouring stage, the primary volume of the recurrence or its surgical bed with/without residual tissue (GTVr) is determined according to the magnetic resonance imaging series T1 and T2/FLAIR. Clinical volume of the CTVr target is determined by spacing 15 mm from GTVr while excluding the intact natural barriers from the volume. Planned target volume PTVr is formed by spacing 3 mm from CTVr. Upon completion of dosimetric planning, a course of proton therapy is carried out with an active scanning proton beam in a physical single focal dose (SFD) of 1.81 Gy to a physical total focal dose (TFD) of 50.68 Gy, that taking into account the relative biological efficiency of proton radiation 1.1 is equivalent to SFD 2.0 Gy and TFD 56 Gy, for 28 fractions per cerebral rHGG region with underlying intravenous introduction of Bevacizumab in dose of 5-10 mg/kg every 2 weeks on 1st, 15th and 30th days of the proton therapy course, respectively.

EFFECT: method provides higher clinical effectiveness in cerebral rHGG in adults by combining physical and radiobiological properties of proton radiation with radiomodifying and cytotoxic effects of Bevacizumab due to high coverage with a radical dose of target volumes of radiation with minimum intersection with previous radiation fields, leading to reduction of radiation toxicity and improvement of overall and recurrence-free survival rate.

1 cl, 3 dwg, 2 ex